What Gets Funded

Each year, The Golden Lights Foundation selects a number of specific projects identified by the medical advisory board to fund. This year one of our current funding projects includes a phase I/II trial for continued advancements in a neuroblastoma therapeutic. We continue to evaluate and select projects from researchers and hospitals across the country based on a number of criteria and evaluated by our medical advisory board.

Phase I/II Clinical Trial for Neuroblastoma


IL-15HC Study Update

With YOUR continued support, as of March 2022, The Golden Lights Foundation has been able to support MSK Kids, who has successfully launched the IL-15HC study.

 This study adds a form of the immune enhancer interleukin-15, IL-15HC, to treatment with the antibody naxitamab (Danyelza®) and GM-CSF, which is an FDA-approved treatment for NB. Because IL-15HC may be more stable and effective than other forms of this immune enhancer, this study — the first to combine IL-15HC, GM-CSF, and antibody therapy — could greatly enhance an already proven effective treatment, especially in patients who have received prior treatment with chemotherapy or other immune-depleting therapies and are most in need of enhanced immunotherapy. As the study continues, we look forward to keeping you updated on its success.

The researchers also hope to determine if any of the antibodies might be used against other cancers such as pediatric leukemia, lymphoma, and breast and colon cancer.

About MSK Kids

MSK Kids, Memorial Sloan Kettering’s pediatric program, is dedicated to all children, young adults, and families facing childhood cancer. With specialized expertise and care focused on the individual child, we’re proud to say that more families turn to us for cancer care than any other hospital in the United States.

Why? Because our care teams work to understand the nature of each patient’s specific cancer, whether it’s common or more complex, and develop individualized treatment plans for the needs of each child. Our broad set of therapies and clinical trials, as well as researchers who continue to develop and deliver more effective treatments where there previously were none, giving each child facing pediatric cancer more options.

But the best care goes beyond treatment, which is why we partner with families to provide support throughout their time at MSK Kids. Our care teams include schoolteachers, therapists, and other specialists to help families through every challenge that pediatric cancer presents. With Memorial Sloan Kettering’s unmatched expertise in cancer and a dedicated focus on kids and young adults, no one fights harder for people facing pediatric cancer than MSK Kids.